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Safety of new medicines in young 
children
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The short report by Tullus (see page 881) 
highlights safety concerns regarding the 
use of angiotensin II receptor blockers 
in preschool children.1 Tullus highlights 
the deaths of three preschool children 
out of the 183 children with hyperten-
sion who received valsartan or candesar-
tan in two clinical trials. One needs to 
recognise that deaths do occur in clinical 
trials. A review of paediatric clinical tri-
als published over a 7-year period identi-
ﬁ  ed deaths in 11% of the clinical trials.2 
In the majority of cases, it was felt by 
both the authors of the review and the 
original authors of the published clini-
cal trials that the deaths were unrelated 
to the investigational drug. There were, 
however, six clinical trials terminated 
early because of signiﬁ  cant drug toxicity, 
as well as two trials where the mortal-
ity was higher in the treatment group. 
Fortunately, the risk of death as a direct 
r e s u l t  o f  d r u g  t o x i c i t y  w i t h i n  p a e d i a t -
ric clinical trials appears to be low. It is 
recognised, however, that drug toxic-
ity is poorly reported in clinical trials.3 
A recent review of over 100 published pae-
diatric clinical trials found that less than 
one in ﬁ  ve of the clinical trials reported 
safety data adequately.3 Clinical trials 
are not the best way of studying drug 
toxicity as they are often underpowered 
to detect severe adverse drug reactions.4
Cases of suspected drug toxicity are 
often reported as individual case reports. 
Individual case reports may subsequently 
be conﬁ   rmed by retrospective reviews 
or by a greater understanding of the 
pathophysiology of the toxicity. A good 
example of the latter is the cardiovascular 
collapse of newborn infants following 
chloramphenicol, which was initially 
described in three newborn infants 
in 1959.5 Subsequent studies of the 
metabolism of chloramphenicol in the 
neonatal period conﬁ   rmed a consider-
ably decreased capacity to metabolise 
chloramphenicol and provided a physi-
ological explanation for the toxicity.6 
Retrospective reviews of all the cases of 
fatal hepatotoxicity secondary to sodium 
valproate reported in the USA between 
1978 and 1984 identiﬁ  ed that the risk of 
hepatotoxicity was greatest in children 
under the age of 3 years and those receiv-
ing other anticonvulsants alongside the 
valproate.7 The cases of ﬁ  ve children who 
died following the use of a propofol infu-
sion as a sedative in critically ill children 
were reported in 1992.8 A subsequent 
review of all the reported cases identi-
ﬁ   ed that prolonged duration and high 
doses were more likely to be associated 
with development of the propofol infu-
sion syndrome (cardiotoxicity, metabolic 
acidosis and liver   damage) in children.9 
Many other suspected cases of drug tox-
icity, however, are neither conﬁ  rmed nor 
refuted. Concern has previously been 
expressed that paediatric case reports of 
individual adverse drug reactions are less 
likely to be reported than adult cases.10
Both the clinical trials of angiotensin II 
receptor blockers were sponsored by the 
pharmaceutical industry. This is appropri-
ate as the pharmaceutical company that 
develops a new product should both spon-
sor clinical trials and publish the results of 
the trials. There have unfortunately been 
several instances where the pharmaceuti-
cal company has failed to publish clinical 
trials when their product has either failed 
to show efﬁ  cacy11   12 or been associated 
with signiﬁ  cant  toxicity.12–14 A review 
of industry sponsored clinical trials of 
antidepressants identiﬁ  ed 74 clinical tri-
als registered with the Food and Drug 
Administration (FDA).11 Thirty-eight of 
these clinical trials reported a positive 
beneﬁ  t of the antidepressant and 37 of 
these were published. In contrast, 22 of 
the 36 studies which failed to show efﬁ  -
c a c y  w e r e  n o t  p u b l i s h e d .  A d d i t i o n a l l y ,  
11 of the 36 studies, which the FDA felt 
fail e d  to  sh o w  e fﬁ  cacy, were published 
with a conclusion suggesting that the 
drug was effective.
Concern has been expressed by dif-
ferent authors about the interpretation 
of safety data by the pharmaceutical 
industry in relation to new products.12–14 
Rofecoxib was withdrawn in 2004. 
A meta-analysis of the risk of cardiotox-
icity, however, showed that by the end of 
2000, data from over 20 000 patients had 
conﬁ   rmed a highly signiﬁ  cant  greater 
r i s k  o f  m y o c a r d i a l  i n f a r c t i o n . 15 The 
authors felt that rofecoxib should have 
been withdrawn several years earlier. 
A review of documents that only became 
available during legal proceedings 
against the manufacturer of rofecoxib 
illustrates how the pharmaceutical com-
pany delayed informing the regulatory 
authorities about an increased number 
of deaths in the treatment group.16 This 
review also highlights how published 
articles suggested that the drug was ‘well 
tolerated’ despite signiﬁ  cantly  greater 
deaths in the treatment arm. There 
have been several new products licensed 
for use in adults which have had to be 
withdrawn because of signiﬁ  cant  drug 
toxicity. Rimonabant, a treatment for 
obesity, was withdrawn in 2008 because 
of its psychiatric toxicity.17 In 2009, the 
oral β-agonist orciprenaline, a treatment 
for asthma, was withdrawn because of 
cardiotoxicity.18 In 2010, rosiglitazone, 
used for adults with type 2 diabetes, was 
withdrawn because of the increased car-
diovascular risk.19 It is fortunately only 
a minority of medicines that need to 
be withdrawn because of drug toxicity. 
However, one always needs to evaluate 
the risk of toxicity against the advan-
tages of treatment.
History has also shown that young 
children may be more prone to speciﬁ  c 
adverse drug reactions than older chil-
dren.20 The retrospective review of cases 
of hepatotoxicity secondary to sodium 
valproate identiﬁ  ed that young children 
under the age of 3 years were at the 
greatest risk.7 Antihistamines are widely 
used in both adults and children. Their 
use in infants under the age of 1 year, 
however, has been shown to increase the 
risk of sleep apnoea, and hence, sudden 
infant death syndrome.21 One therefore 
needs to be aware that the safety proﬁ  le 
of medicines may be different within dif-
ferent paediatric age groups.
New medicines can result in a signiﬁ  -
cant improvement in reducing morbidity 
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and mortality. However, one has also to 
be aware that the safety proﬁ  le of a new 
medicine is not established until it has 
been extensively used for several years. 
It would seem sensible to use angiotensin 
II receptor blockers more extensively in 
older children, and thus establish more 
safety data, before rushing to use them in 
preschool children.
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